ИСТИНА	Войти в систему Регистрация
	Интеллектуальная Система Тематического Исследования НАукометрических данных
	Главная Поиск Статистика О проекте Помощь

---

Annals of Oncologyжурнал

Статьи, опубликованные в журнале

• • 2022 426P - Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study
  • Rumyantsev A., Glazkova E., Manukyan M., Darenskaya A., Lud H., Tryakin A., Tyulyandina A.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 33, № S9
• • 2022 541P - Efficacy of various anticancer agents after failure of maintenance olaparib: A retrospective study
  • Rumyantsev A., Tyulyandina A., Glazkova E., Pokataev I., Tjulandin S.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 33, № suppl_7, с. S235-S282 DOI
• • 2022 ISSN 0923-7534
  • Filonenko D., Zhukova L., Arkhiri P., Nikulin M., Sagaidak I., Yugay V., Meshcheryakov A.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 33, № 4, с. 319
• 
  • 2021 24P Using real-world evidence data and machine learning to identify molecular biomarkers for patient response to immune checkpoint inhibitors in metastatic melanoma
  • Siozopoulou V., Khmelevskiy A., Rodlauer-Kriegl A., de Caluwe T., Churov A., Valyaeva A., Bruyen L.De, Wener R., Specenier P., Cuvelier C., Thienpont M., Richtig E., Pauwels P.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, с. S1383 DOI
• • 2021 71P Breast cancer cells’ taxol-resistance is associated with cytoplasmic actin isoforms balance shift and acquisition of more malignant phenotype
  • Novikova M.V., Dugina V.B., Boichuk S.V., Kopnin B.P.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 6, с. S1367-S1367 DOI
• 
  • 2021 Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
  • Harbeck N., Rastogi P., Martin M., Tolaney S.M., Shao Z.M., Fasching P.A., Huang C.S., Jaliffe G.G., Tryakin A., Goetz M.P., Rugo H.S., Senkus E., Testa L., Andersson M., Tamura K., Mastro L.Del, Steger G.G., Kreipe H., Hegg R., Sohn J., Guarneri V., Cortés J., Hamilton E., André V., Wei R., Barriga S., Sherwood S., Forrester T., Munoz M., Shahir A., Antonio B.San, Nabinger S.C., Toi M., Johnston S.R.D, O’Shaughnessy J., Jimenez M.M., Johnston S., Boyle F., Steger G.G., Neven P., Jiang Z., Campone M., Huober J., Shimizu C., Cicin I., Wardley A., Tolaney S.M., Abuin G.G., Zarba J., Lim E., Sant P., Liao N., Christiansen B., Eigeliene N., Martin-Babau J., Ettl J., Mavroudis D., Chiu J., Boer K., Nagarkar R., Paluch-Shimon S., Moscetti L., Sagara Y., Kim S.B., Maciel M.M., Tjan-Heijnen V., Broom R., Lacko A., Schenker M., Volkov N., Yap Y.Sim, Coccia-Portugal M., Sáenz J.Ángel García, Andersson A., Chao T.Y., Gokmen E., Harputluoglu H., Berzoy O., Patt D., McArthur H., Chew H., Chalasani P., Kaufman P., Tedesco K., Graff S.L.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 12, с. 1571-1581 DOI
• 
  • 2021 Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
  • Harbeck N., Rastogi P., Martin M., Tolaney S.M., Shao Z.M., Fasching P.A., Huang C.S., Jaliffe G.G., Tryakin A., Goetz M.P., Rugo H.S., Senkus E., Testa L., Andersson M., Tamura K., Mastro L.Del, Steger G.G., Kreipe H., Hegg R., Sohn J., Guarneri V., Cortés J., Hamilton E., André V., Wei R., Barriga S., Sherwood S., Forrester T., Munoz M., Shahir A., Antonio B.San, Nabinger S.C., Toi M., Johnston S.R.D, O’Shaughnessy J., Jimenez M.M., Johnston S., Boyle F., Steger G.G., Neven P., Jiang Z., Campone M., Huober J., Shimizu C., Cicin I., Wardley A., Tolaney S.M., Abuin G.G., Zarba J., Lim E., Sant P., Liao N., Christiansen B., Eigeliene N., Martin-Babau J., Ettl J., Mavroudis D., Chiu J., Boer K., Nagarkar R., Paluch-Shimon S., Moscetti L., Sagara Y., Kim S.B., Maciel M.M., Tjan-Heijnen V., Broom R., Lacko A., Schenker M., Volkov N., Yap Y.Sim, Coccia-Portugal M., Sáenz J.Ángel García, Andersson A., Chao T.Y., Gokmen E., Harputluoglu H., Berzoy O., Patt D., McArthur H., Chew H., Chalasani P., Kaufman P., Tedesco K., Graff S.L.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 12, с. 1571-1581 DOI
• 
  • 2021 Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
  • Burstein H.J., Curigliano G., Thürlimann B., Weber W.P., Poortmans P., Regan M.M., Senn H.J., Winer E.P., Gnant M., Aebi Stephan, André Fabrice, Barrios Carlos, Bergh Jonas, Bonnefoi Herve, Morales Denisse Bretel, Brucker Sara, Burstein Harold, Cameron David, Cardoso Fatima, Carey Lisa, Chua Boon, Ciruelos Eva, Colleoni Marco, Curigliano Giuseppe, Delaloge Suzette, Denkert Carsten, Dubsky Peter, Ejlertsen Bent, Fitzal Florian, Francis Prudence, Galimberti Viviana, Mahmoud Hebatallah Gamal El Din Mohamed, Garber Judy, Gnant Michael, Gradishar William, Gulluoglu Bahadir, Harbeck Nadia, Huang Chiun-Sheng, Huober Jens, Ilbawi Andre, Jiang Zefei, Johnston Steven, Lee Eun Sook, Loibl Sibylle, Morrow Monica, Partridge Ann, Piccart Martine, Prat Aleix, Regan Meredith, Rubio Isabella, Rugo Hope, Rutgers Emiel, Sedlmayer Felix, Semiglazov Vladimir, Senn Hans-Joerg, Shao Zhiming, Spanic Tanja, Tesarova Petra, Thürlimann Beat, Tjulandin Sergei, Toi Masakazu, Trudeau Maureen, Turner Nicholas, Luis Inez Vaz, Viale Giuseppe, Watanabe Toru, Weber Walter P., Winer Eric P., Xu Binghe
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 10, с. 1216-1235 DOI
• • 2021 DNMT1/3-targeting microRNAs are over-expressed in the exosomes of estrogen-resistant breast cancer cells
  • Sorokin D., Andreeva O., Mikhaevich E., Shchegolev Y., Sigin V., Strelnikov V., Tanas A., Scherbakov A., Krasilnikov M.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 1 DOI
• • 2021 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
  • 40 Fedyanin, Mikhail, Moiseenko F., Lyadova M., Vorobeva E., Gladkov O., Petkau V., Fateeva A., Kuzmina E., Novikova O., Chubenko, Viacheslav, Abduloeva N., Kudryavtsev A., Ignatova E., Shakirov R., Pardabekova O., Kindyalova L., Pelikh S., Tjulandin, Sergei, Tryakin, Alexey
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32
• • 2021 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
  • 40 Fedyanin, Mikhail, Moiseenko F., Lyadova M., Vorobeva E., Gladkov O., Petkau V., Fateeva A., Kuzmina E., Novikova O., Chubenko, Viacheslav, Abduloeva N., Kudryavtsev A., Ignatova E., Shakirov R., Pardabekova O., Kindyalova L., Pelikh S., Tjulandin, Sergei, Tryakin, Alexey
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32
• 
  • 2021 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
  • Sahin1 U., 2, 3, Türeci3, 4, Manikhas5 G., Lordick6 F., Rusyn7 A., Vynnychenko8 I., Dudov9 A., Bazin I., Bondarenko11 I., Melichar12 B., Dhaene13 K., Wiechen14 K., Huber1 C., 3, 4, Maurus15 D., Arozullah16 A., Park16 J.W., Schuler17y M., Al-Batran18* S.E.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 5, с. 609-619 DOI
• • 2021 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
  • Sahin1 U., 2, 3, Türeci3, 4, Manikhas5 G., Lordick6 F., Rusyn7 A., Vynnychenko8 I., Dudov9 A., Bazin1 I., Bondarenko11 I., Melichar12 B., Dhaene13 K., Wiechen14 K., Huber1 C., 3, 4, Maurus15 D., Arozullah16 A., Park16 J.W., Schuler17y M., Al-Batran18* S.E.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 5, с. 609-619 DOI
• • 2021 Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN)
  • MH Taylor, Leboullex S., Panaseykin V., Konda B., de la Fourchardiere C., Hughes BGM, Gianoukakis AG, Park YJ, Romanov I., Krzyzanowska MK, Garbinsky D., Sherif B., Pan JJ, Binder T., Sauter N., Xie R., Brose MS
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, с. 1205-1210 DOI
• 
  • 2021 Influence of the expression of ABCG2 transporters on the results of photodynamic therapy in malignant gliomas
  • Рында Артемий Юрьевич, Олюшин Виктор Емельянович, Ростовцев Дмитрий Михайлович, Забродская Юлия Михайловна
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № Suppl. 5, с. S523 DOI
• • 2021 Low glucose sensitizes A431 skin cancer cells to metformin treatments: way forward to targeting PD-L1
  • Mikhaylova A.L., Basharina A.A., Sorokin D.V., Buravchenko G.I., Samsonik S.A., Bogush T.A., Scherbakov A.M.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 6, с. 1360 DOI
• • 2021 Molecular profiling of tumor tissue and tumor-derived cell lines in patients with glioblastoma
  • Nasedkina T., Varachev V., Susova O., Krasnov G., Poletaeva A., Mitrofanov A.A., Naskhletashvili D., Bekyashev A.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), № 32, с. 519-519
• 
  • 2021 Nuclear structures upon changes in the expression of cytoplasmic actin isoforms
  • Dugina V.B., Panina S.D., Novikova M.V., B Kopnin P.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 6, с. S1366-S1366 DOI
• 
  • 2021 Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
  • Miles D., Gligorov J., André F., Cameron D., Schneeweiss A., Barrios C., Xu B., Wardley A., Kaen D., Andrade L., Semiglazov V., Reinisch M., Patel S., Patre M., Morales L., Patel S.L., Kaul M., Barata T., O’Shaughnessy J., Zhang Q., Xu B., Shao Z., Wang X., Geng C., Yan X., Tong Z., Shen K., Yin Y., Sun T., Yang J., Feng J., Yan M., Wang Y., Liu Q., Zhang S., Laurentiis M.De, Santoro A., Guarneri V., Colleoni M., Natoli C., Cortesi L., Placido S., Gianni L., Ferrau F., Livi L., Zambelli A., Mastro L.Del, Tonini G., Montemurro F., Bianchi G., Pedersini R., Prete S., Allegrini G., Naso G., Vici P., Loirat D., Mailliez A., Priou F., Tredan O., Dalenc F., Perrin C., David M.Timar, Dohollou N., Teixeira L., Brocard F., Arnaud A., Delaloge S., Spano J.P., Mansi L., Damian F., Pedrini J., Aleixo S., Hegg R., Junior R., Reinisch M., Schmidt M., Wenzel C., Grischke E.M., Schneeweiss A., Just M., Harbeck N., Schumacher C., Peters U., Fischer D., Forstbauer H., Liersch R., Warner E., Bouganim N., Doyle C., Hiller J.Price, Vandenberg T., Pavic M., Robinson A., Urgoiti G.Roldan, Califaretti N., Alacacioglu A., Gumus M., Yalcin B., Cicin I., Kose F., Uygun K., Kaplan M., Cubukcu E., Harries M., Miles D., Doval D., Gupta S., Mohapatra P., Chatterjee S., Ghadyalpatil N., Singhal M., Nag S., Agarwal A., Wolf I., Yam E.Gal, Yerushalmi R., Peretz T., Fried G., Baruch N.Ben, Katz D., Hamilton E., Kayali F., Brufsky A., Telli M., Wright G., Oyola R., Rakowski T., Graff S., Tjulandin S., Semiglazov V., Aparicio A., Borrego M.Ruiz, Merino L., Martinez J.Guerra, Lopez E., Yamashita T., Ohtani S., Inoue K., Ito Y., Niikura N., Nakayama T., Sagara Y., Yanagita Y., Kamada Y., Kaneko K., Kaen D., Nervo A., Eniu A., Schenker M., Priester P., Melichar B., Zimovjanova M., Sormova P., Sufliarsky J., Kakalejcik M., Belbaraka R., Errihani H., Than D.Le, Pham D., Aravantinos G., Papadimitriou C., Koumakis G., Papandreou C., Podolski P., Tabane K.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 8, с. 994-1004 DOI
• • 2021 The amount of cancer stem cells and the sensitivity to anticancer drugs in glioblastoma primary cell culture
  • Susova O., Poletaeva A., Lupatov A., Kholodenko I., Karamysheva A., Mitrofanov A.A., Naskhletashvili D., Nasedkina T., Bekyashev A.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), № 32, с. 519-519
• • 2021 Transient multiple transfection of miR-181a into MCF-7 breast cancer cells induces irreversible resistance to tamoxifen
  • Andreeva O.E., Shatskaya V.A., Sorokin D.V., Scherbakov A.M., Mikhaevich E.I., Gudkova M.V., Bure I.V., Kuznetsova E.B., Nemtsova M.V., Krasilnikov M.A.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 32, № 6 DOI
• 
  • 2020 14P Modulation of MCF-7 cell sensitivity to anticancer agents by targeting glycolysis
  • Scherbakov A.M., Sorokin D., Omelchuk O., Shchekotikhin A., Krasil’nikov M.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 31, с. S249-S249 DOI
• 
  • 2020 21P Urethane-induced lung carcinogenesis in genetically edited C57Bl/6 mice with CHEK2 and GPRC5A heterozygous inactivating mutations
  • Imyanitov E., Panchenko A., Permyakov O., Maydin M., Yurova M., Aleksakhina S., Averina O., Sergiev P.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 31, с. S251-S251 DOI
• 
  • 2020 408P Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
  • Maevskaya J., Laktionov K., Yudin D., Vladimirova L.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 31, с. S1402-S1402 DOI
• 
  • 2020 42P Imatinib mesylate (IM) promotes malignant behaviour of IM-resistant gastrointestinal stromal tumours (GISTs) via activation of FGF-signaling
  • Boichuk S., Mikheeva E., Sabirov A., Petrov S., Novikova M., Kopnin P., Valeeva E.
  • в журнале Annals of Oncology, издательство Oxford University Press (United Kingdom), том 31, с. S1230 DOI